tiprankstipranks
Curis announces additional data from TakeAim leukemia study
The Fly

Curis announces additional data from TakeAim leukemia study

Curis (CRIS)presented data from the TakeAim Leukemia study in relapsed/refractory, or R/R, Acute Myeloid Leukemia or AML, at the 66th ASH annual meeting. The additional data presented include data for 21 patients with a FLT3 mutation who had received fewer than 3 lines of prior therapy and were treated with emavusertib as monotherapy at the Recommended Phase 2 Dose of 300 mg BID. This brings the total number of patients dosed at the RP2D from 12 to 21 patients. Data show 10 objective responses in 19 response-evaluable patients: 6 complete remission or CR, 2 CR with either a complete remission with incomplete hematological recovery or a partial hematological recovery and 2 morphologic leukemia-free state. Prior Two patients who achieved a CR and CRi, respectively, proceeded to allogenic stem cell transplantation. Responses were achieved rapidly in this population, with 7 of 10 responses reported at the first assessment on Cycle 2 Day 1.

Pick the best stocks and maximize your portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App